PR Newswire
REHOVOT, Israel , Dec. 21, 2023 /PRNewswire/ -- Biomica Ltd. , a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd . (Nasdaq: EVGN) (TASE: EVGN), is gearing up for participation in the JP Morgan 42 nd Annual Healthcare Week, scheduled to run from January 8 to 11, 2024 , in San Francisco . Biomica will also be taking part in the Biotech Showcase conference.
Dr. Elran Haber, CEO of Biomica, will be available for one-on-one meetings throughout the week, starting on Monday, January 8 , and concluding on Thursday, January 11, 2024 . Those interested in scheduling a meeting with Dr. Haber can reach out to Biomica's investor or public relations team."
About Biomica Ltd.:
Biomica is a clinical stage biopharmaceutical company developing innovative microbiome-based therapeutics utilizing PRISM system, a proprietary computational platform powered by Evogene's MicroBoost AI tech-engine. licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN).
For more information, please visit www.biomicamed.com .
About Evogene Ltd.:
Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique tech-engines - MicroBoost AI , ChemPass AI and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes ( MicroBoost AI ), small molecules ( ChemPass AI ), and genetic elements ( GeneRator AI ).
Evogene uses its tech-engines to develop products through subsidiaries and strategic partnerships. Evogene's subsidiaries currently utilize the tech-engines to develop human microbiome-based therapeutics by Biomica, ag-biologicals by Lavie Bio , ag-chemicals by AgPlenus, medical cannabis products by Canonic and castor varieties, for the biofuel and other industries, by Casterra.
For more information, please visit: www.evogene.com .
Contacts
Rachel Pomerantz Gerber
Head of Investor Relations at Evogene
rachel.pomerantz@evogene.com
Tel: +972-8-9311901
SOURCE Biomica Ltd.